A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML. The median age was 74 years, and a m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lancet, Jeffrey E., Gojo, Ivana, Gotlib, Jason, Feldman, Eric J., Greer, Jacqueline, Liesveld, Jane L., Bruzek, Laura M., Morris, Lawrence, Park, Youn, Adjei, Alex A., Kaufmann, Scott H., Garrett-Mayer, Elizabeth, Greenberg, Peter L., Wright, John J., Karp, Judith E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2007
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1794070/
https://ncbi.nlm.nih.gov/pubmed/17082323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-04-014357
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados